Replies to post #218199 on Biotech Values

[DewDiligence]

Mavyret’s US market share hits new highs in week ending 4/6/18 (according to IMS)…

• ABBV/ENTA’s NRx share=44.5%, +110 basis points from the previous week (the prior highest).

• ABBV/ENTA’s TRx share=40.3%, +170 basis points from the previous week (the prior highest) and +310 basis points from the week ending 3/23/18.

(Almost all of ABBV/ENTA’s US HCV business now comes from Mavyret.)